Drug intelligence / Profile preview

cerebraca wafer + temozolomide

Development stage
Unknown
Lead developer
Everfront Biotech
Modality
Small Molecules
Administration
Intracranial, Oral
01

Overview

Cerebraca Wafer + temozolomide is a combination therapy designed for the treatment of brain tumors, particularly high-grade gliomas and glioblastoma. **Cerebraca Wafer** is an implantable local drug delivery system that releases its active pharmaceutical ingredient (commonly targeting cell proliferation and survival pathways) directly into the tumor resection cavity post-surgery, aiming to maximize local antitumor effect and minimize systemic toxicity. **Temozolomide** is an oral alkylating chemotherapy agent that works by methylating DNA, leading to tumor cell death, and is standard-of-care in combination with radiation and/or other modalities for glioblastoma and other high-grade brain tumors. This combination aims to synergize local (wafer-based) and systemic (oral) chemotherapeutic effects to improve progression-free and overall survival for patients with malignant brain tumors. The primary indication is for high-grade gliomas, including glioblastoma multiforme.

Other names
tmz
02

Targets

AGT (O6-methylguanine-DNA methyltransferase)EGFR (Epidermal growth factor receptor)AXL (AXL receptor tyrosine kinase)DNA

Beyond the preview

Go deeper on cerebraca wafer + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cerebraca wafer + temozolomide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call